ERBB2 and breast cancer: Non‐Hispanic White patients were less likely to have advanced stage of BC at presentation (13.2%, 95% CI: 12–15%), more likely to have hormone receptor‐positive (HR +) and HER2‐negative tumors (HER2−) (71.7%, 95% CI: 56–61%), and less likely to have triple‐negative BC (8.5%, 95% CI: 7–10%) compared to the other ethnic groups.